Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer

Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer

Purpose: Osimertinib is a third-generation EGFR-TKI and preferred first-line (1L) treatment for EGFR positive (EGFR+) metastatic non-small cell lung cancer (mNSCLC). This study compared real-world clinical outcomes of 1L osimertinib versus 1st or 2nd generation EGFR-TKIs (1/2G-TKIs) in patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Kibum Kim, Sakil Syeed, Trang Au, Amber Diaz, Matthew B. Schabath, Amanda Cass, Richard Hall, Lori Pai, Chenghui Li, Nicole Balmaceda, Alison Palumbo, Autumn Carey, Mumtu Lalla, Matthew Henry, Diana Brixner, David Stenehjem
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Metastatic non-small cell lung cancer
EGFR-TKI
Multi-site research
Clinical outcomes
Healthcare resource utilization
Online Access:http://www.sciencedirect.com/science/article/pii/S246829422500036X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S246829422500036X

Similar Items